pde10a

PDE10A-IN-8 is a potent inhibitor of PDE10A.

Compound 8a (PDE10A-IN-3) serves as an inhibitor of phosphodiesterase 10A (PDE10A) and is utilized in schizophrenia research [1].

N-Methylbenzamide is a potent inhibitor of phosphodiesterase 10A (PDE10A) with demonstrated anti-cancer activity.

PQ-10 (A-844337) is a PDE-10 inhibitor. PQ-10 induces brain glucose metabolism patterns, which may be a potential translational biomarker.

THPP-1 is a potent and orally bioavailable inhibitor of PDE10A(Ki of 1 nM and 1.3 nM for human and rat PDE10A, respectively).

AMG 579 is an efficacious and selective inhibitor of PDE10A (IC50 = 0.1 nM).

TP-10 is a selective inhibitor of PDE10A against other PDEs with IC50 of 0.8 nM.

PDE5-IN-2 is a potent, highly selective, and orally active inhibitor of PDE5 (IC50 of 0.31 nM).

MK-8189 is a potent, orally active, and selective inhibitor of Phosphodiesterase 10A (PDE10A), with a K i value of 29 pM, offering potential applications in schizophrenia research.

Balipodect (TAK063) is a highly effective and selective PDE10A inhibitor (IC50: 0.30 nM); Its selectivity is >15000-fold over other PDEs.

MT-3014 is a potent, highly selective, and brain-penetrant inhibitor of phosphodiesterase 10A (PDE 10A), with IC50 values of 0.062 nM for human PDE 10A and 0.09 nM for bovine PDE 10A.

WAY-620445 is an active molecule [1]. It is a potent and selective inhibitor of phosphodiesterase 10A (PDE10A) with an IC50 of 1.8 nM. This compound has demonstrated efficacy in preclinical models of psychosis and is being explored as a potential therapeutic agent for schizophrenia.

Gemlapodect (RO554965), a phosphodiesterase 10A (PDE10A) inhibitor, is utilized in schizophrenia research.

PDE10A inhibitor

PDM-042 is a potent and selective orally active phosphodiesterase 10A (PDE10A) inhibitor, demonstrating strong inhibitory activities for human and rat PDE10A with IC50 values below 1 nM and over 1000-fold selectivity against other phosphodiesterases. PDM-042 can be used for schizophrenia research [1].

Mardepodect hydrochloride (Mardepodect HCl) is an orally active, selective and potent inhibitor of PDE10A that crosses the blood-brain barrier (IC50: 0.37 nM).Mardepodect hydrochloride up-regulates the expression of proteins encoding specific growth and transcription factors, cell signalling molecules and cell surface proteins. Mardepodect hydrochloride upregulates genes encoding specific growth factors, transcription factors, cell signalling molecules, and cell surface proteins, while downregulating a broad spectrum of cell cycle and apoptosis-related genes.

MP-10 succinate is a potent and specific inhibitor of PDE10A.

THPP-4 inhibits phosphodiesterase 10A (PDE10A).

HPP-2 is a novel phosphodiesterase 10A (PDE10A) inhibitor used to treat schizophrenia.

JNJ-42314415 is a potent, specific, and centrally active inhibitor of PDE10A.

[11C]MP 10 (PF-2545920), a specific and effective PDE10A inhibitor (IC50=0.37 nM), is with more than1000-fold specificity activity over the PDE.

Mardepodect (PF-2545920) is a phosphodiesterase inhibitor selective for the PDE10A subtype with an IC50 of 0.37 nM and over 1000-fold selectivity over PDE. It is potentially useful for the treatment of schizophrenia. Phosphodiesterase 10A (PDE10A) is highly expressed in striatal medium spiny neurons of both the direct and indirect output pathways. Mardepodect can cross the blood-brain barrier.

PDE2 PDE10-IN-1 is an inhibitor of phosphodiesterase 2 (PDE2) and PDE10, with IC50 values of 29 nM and 480 nM, respectively.